Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.

ABSTRACT:

Background

Nivolumab is an anti-PD1 checkpoint inhibitor active in patients with advanced melanoma and as adjuvant therapy in high-risk metastatic melanoma patients.

Methods

In this single-center retrospective analysis, we investigated the CD73 enzyme activity in patients with metastatic melanoma stage IV and its correlation with the response to nivolumab. The soluble CD73 (sCD73) enzyme activity was measured in the serum of 37 melanoma patients before receiving nivolumab and the Harrel's C index was used to find the best cut-off for this biomarker. The multivariate Cox proportional hazard model was used to evaluate the prognostic value of CD73 enzyme activity for survival and progression-free survival.

Results

Our results show that high levels of sCD73 enzyme activit

SUBMITTER: Morello S 

PROVIDER: S-EPMC5716054 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature